当地时间2月6日,跨国药企阿斯利康发布2024年年度财报,透露了一好一坏两则重磅消息。一方面,公司2024年中国区收入创下历史新高;另一方面,阿斯利康或因涉嫌偷税将面临最高450万美元的罚款。中国区收入创历史新高2024年财报数据显示,阿斯利康全年营收540.73亿美元,同比增长21%;第四季度实现营收148.91亿美元,同比增长25%。从细分业务看,肿瘤业务(Oncology)依然是阿斯利康表现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.